Antibodies as Drugs

抗体作为药物

基本信息

批准号：
9042880
负责人：
DAVID L. WOODLAND
金额：
$ 0.7万
依托单位：
KEYSTONE SYMPOSIA
依托单位国家：
美国
项目类别：
财政年份：
2016
资助国家：
美国
起止时间：
2016-02-10 至 2017-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9042880
关键词：
Academia Address Antibodies Area Attention Autoimmunity Biology British Columbia Canada Cancer Vaccines Cell Therapy Clinical Collaborations Communicable Diseases Communities Development Diagnosis Disease Drug Approval Drug Carriers Drug Targeting Engineering Failure Generations Goals Government Head Imaging technology Immune system Immunology Immunotherapy Industry Inflammatory Institutes Investigation Lead Malignant Neoplasms Medicine Mission Molecular Monoclonal Antibodies National Institute of Allergy and Infectious Disease Oncogenes Outcome Pathway interactions Pharmaceutical Preparations Property Protein Engineering Radioisotopes Research Research Institute Research Personnel Scientist Specificity Staging Structure Students Technology Therapeutic Therapeutic Human Experimentation Therapeutic antibodies Vaccine Research Work antibody engineering base cancer immunotherapy cancer therapy cytokine imaging agent improved macromolecule meetings mimetics next generation oncology posters public health relevance symposium

项目摘要

DESCRIPTION (provided by the applicant): Support is requested for a Keystone Symposia meeting entitled Antibodies as Drugs, organized by Peter D. Senter, Anna M. Wu, Alan J. Korman and Karl Dane Wittrup. The meeting will be held in Whistler, British Columbia, Canada from March 6-10, 2016. Monoclonal antibodies have had a pronounced impact in medicine and biology, with a broad array of approved agents that are used for the diagnosis, treatment and characterization of cancers, immunological disorders, and infectious diseases. Because of their exquisite target specificities, together with their favorable pharmacologic properties, antibodies are destined to have even increased clinical impact, particularly in diseases that are understood at the molecular level. This Keystone Symposia meeting will focus attention on many of the key advances in antibody-based technologies as well as on where the field is heading. Some of the critical topics that will be include: 1) Antibody structure and function; 2) Engineered antibodies and antibody-like molecules for improved efficacy; 3) Antibody pharmacologic properties and biologic distribution; 4) Antibody-based therapies for cancer and infectious diseases; 5) Targeting co-stimulatory pathways and immunological checkpoints; 6) Antibodies as carriers of drugs, cytokines, radioisotopes and imaging agents; 7) Antibody mimetics; and 8) Clinical advancements and challenges. This meeting has become an established forum that attracts both new investigators and leaders in the field, coming from academia, industry and research institutes around the globe. The goals of the meeting will be to address the critical issues facing the broad field of antibody-based therapeutics, provide an overview of recent advances and bring together interdisciplinary groups for the generation of new ideas and promising areas of investigation. Opportunities for interdisciplinary interactions will be significantly enhanced by te concurrent meeting on Cancer Vaccines: Targeting Cancer Genes for Immunotherapy, which will share two plenary sessions with this meeting. The general topic of this meeting is relevant to the NIAID mission given the strong emphasis the meeting will have on immunological mechanisms for the treatment of cancer and other diseases.

描述（由适用的提供）：请求支持Keystone研讨会会议，标题为“抗体为药物”，由Peter D. Senter，Anna M. Wu，Alan J. Korman和Karl Dane Wittrup组织。这次会议将于2016年3月6日至10日在加拿大不列颠哥伦比亚省的惠斯勒举行。单克隆抗体对医学和生物学产生了明显的影响，并具有广泛的批准药物，用于诊断，治疗和特征的癌症，免疫疾病和感染性疾病。由于其独特的目标规格，以及其有利的药物特性，抗体注定要增加临床影响，尤其是在分子水平上被理解的疾病中。这次Keystone研讨会会议将关注基于抗体技术的许多关键进步以及该领域的发展方向。将包括一些关键主题：1）抗体结构和功能； 2）工程抗体和抗体样分子，以提高效率； 3）抗体药理特性和生物分布； 4）基于抗体的癌症和传染病疗法； 5）针对共刺激途径和免疫学检查点； 6）抗体作为药物，细胞因子，放射性同位素和成像剂的载体； 7）抗体模拟物； 8）临床进步和挑战。这次会议已成为一个既定的论坛，吸引了该领域的新调查人员和领导者，来自世界各地的学术界，工业和研究机构。会议的目标是解决面临的关键问题基于抗体的疗法的广泛领域概述了最近的进步，并将跨学科的群体汇集在一起，以产生新的思想和投资领域。通过关于癌症疫苗的同时开会，将大大增加跨学科互动的机会：针对癌症基因进行免疫疗法，这将在这次会议上共享两次全体会议。这次会议的一般话题与鉴于强烈重点，会议将对癌症和其他疾病治疗的免疫学机制具有强烈的重视。